819 32 2788 3 14647 document 2788 Master_Document_819.doc application/msword f04167cac7ddec2f196fd918e4efa1e4 MD5 512512 2019-05-14 15:04:00 https://researchdata.gla.ac.uk/819/1/Master_Document_819.doc 819 1 2 application/msword Text en public cc_by_4

Master_Document_819.doc

documentation 2789 5 14649 document 2789 Data_Collection_Instruments_819.zip application/x-zip fc69ac7e9527ce9ee79983442f43e419 MD5 1576640 2019-05-14 15:04:25 https://researchdata.gla.ac.uk/819/2/Data_Collection_Instruments_819.zip 819 2 3 application/x-zip Text en public cc_by_4

Data_Collection_Instruments_819.zip

documentation 2790 1 14653 document 2790 indexcodes.txt text/plain 29b038724b6edc9efe9f4ed53f0cf8d3 MD5 6817 2019-05-14 15:14:14 https://researchdata.gla.ac.uk/819/3/indexcodes.txt 819 3 3 text/plain other Generate index codes conversion from Text to indexcodes en public

indexcodes.txt

http://eprints.org/relation/isVersionOf https://researchdata.gla.ac.uk/id/document/2788 http://eprints.org/relation/isVolatileVersionOf https://researchdata.gla.ac.uk/id/document/2788 http://eprints.org/relation/isIndexCodesVersionOf https://researchdata.gla.ac.uk/id/document/2788 3127 3 17112 document 3127 ReadMe_819.docx application/vnd.openxmlformats-officedocument.wordprocessingml.document 40b3ab84d22d39e8fa1aa075d96d4e6d MD5 21702 2019-09-26 11:32:59 https://researchdata.gla.ac.uk/819/4/ReadMe_819.docx 819 4 1 application/vnd.openxmlformats-officedocument.wordprocessingml.document Text en public cc_by_4

ReadMe_819.docx

readme 3128 1 17117 document 3128 indexcodes.txt text/x-c++ 34b263937af60afeaafc4629c0c31244 MD5 2873 2019-09-26 11:46:40 https://researchdata.gla.ac.uk/819/5/indexcodes.txt 819 5 5 text/x-c++ other Generate index codes conversion from Text to indexcodes en public

indexcodes.txt

http://eprints.org/relation/isVersionOf https://researchdata.gla.ac.uk/id/document/3127 http://eprints.org/relation/isVolatileVersionOf https://researchdata.gla.ac.uk/id/document/3127 http://eprints.org/relation/isIndexCodesVersionOf https://researchdata.gla.ac.uk/id/document/3127 archive 6975 disk0/00/00/08/19 2019-09-26 12:03:15 2021-06-15 07:47:46 2019-09-26 12:03:15 data_collection show Paul James 6898 0000-0001-7367-5816 Boyd Kathleen 7934 0000-0002-9764-0113 Briggs Andrew 1988 0000-0002-0777-1997 Cassidy James 6193 Harkin Andrea 2133 Iveson Tim http://www.loc.gov/loc.terms/relators/WAM Hanna Catherine glaresearchdata:2019-05-13-819 25102000 25600000 Anyone requesting access to the data associated with this record will be put in contact with the University of Glasgow Clinical Trials Unit who will process the request in accorance with their procedures. Re-users of this data will be expected to recognise SCOT authors/CTU in any future publications by authorship if possible for the key Investigators and CTU team. All other SCOT authors, contributors and sites should be acknowledged. This will be covered by a DTA associated with reuse of the data. 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862. 2019-05-13 University of Glasgow 10.5525/gla.researchdata.819 Other 43058 1 SCOT - short course oncology therapy - a study of adjuvant chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 groups James Paul Medical Research Council (MRC) G0601705 RI CANCER SCIENCES 65935 1 Extension of Follow-Up for High Risk Stage II Patients (additional 3 years) and Stage III Patients (up to year 3 follow-up) in the SCOT study. James Paul National Institute for Health Research (NIHR) 14/140/84 MVLS ICS - CLINICAL TRIALS UN. GARTNAVEL 61537 5 Cancer Research UK Clinical Trials Unit - Core Programme Funding Robert Jones Cancer Research UK (CRUK) 15960 RI CANCER SCIENCES 47462 5 CRUK Clinical Trials Unit Glasgow - Quinquennial review James Paul Cancer Research UK (CRUK) C6716/A9894 MVLS ICS - CLINICAL TRIALS UN. GARTNAVEL FALSE English 2008-03 2016-11 TRUE 07/S0703/136 nhs Ethics details: West GLASGOW REC1 07/S0703/136 21 January 2008 TRUE http://eprints.gla.ac.uk/id/eprint/156527 http://eprints.gla.ac.uk/id/eprint/167742 http://eprints.gla.ac.uk/id/eprint/160340